Catalent, Inc. (CTLT)

55,92 +0,12 (+0,22%) Alla chiusura: 04:00PM EDT

Catalent, Inc.

14 Schoolhouse Road
Somerset, NJ 08873
United States
732 537 6200
https://www.catalent.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 18.000

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Alessandro Maselli	President, CEO & Director	1,08M	N/D	1972
Dr. Aristippos Gennadios Ph.D.	Group President of Pharma & Consumer Health Segment	799,26k	N/D	1966
Mr. Ricky Hopson	President, Division Head for BioProduct Delivery & Chief of Staff	622,12k	N/D	1977
Mr. John J. Greisch M.B.A.	Executive Chairman of the Board	125k	N/D	1955
Mr. Matti M. Masanovich	Senior VP & CFO	N/D	N/D	1972
Mr. Michael J. Hatzfeld Jr.	VP & Chief Accounting Officer	N/D	N/D	1973
Mr. Charles Lickfold	Senior VP & Chief Information Officer	N/D	N/D	1974
Mr. Paul Surdez	Vice President of Investor Relations	N/D	N/D	N/D
Mr. Joseph A. Ferraro J.D.	Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary	N/D	N/D	1978
Mr. Michael J. Grippo	Senior Vice President of Strategy & Corporate Development	N/D	N/D	1969

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Governance aziendale

L'ISS Governance QualityScore di Catalent, Inc. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 8; diritti degli azionisti: 7; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.